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mitogen-activated protein kinase-kinase 3
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Background: microRNA 21 (miR-21) has been demonstrated to be significantly elevated in many types of cancers,
including the hepatocellular carcinoma (HCC). In the present study, we investigated the role of miR-21 in HCC by
identifying its novel targets, as well as its underlying molecular mechanism.
Methods: The expression of mitogen-activated protein kinase-kinase 3 (MAP2K3) in human HCC tumor tissues and
adjacent non-tumor tissues was determined by immunohistochemistry staining (IHC) analysis. The 3’-untranslated
region (3’-UTR) of MAP2K3 combined with miR-21 was experimentally verified by a miRNA luciferase reporter
approach. Moreover, the role of miR-21 in regulating HCC cell proliferation was analyzed by an MTT assay infected
with miR-21mimics/sponge inhibitor Adenoviral viral vectors.
Results: By immunohistochemistry staining analysis, we found that mitogen-activated protein kinase-kinase
3 (MAP2K3) was strikingly repressed in the human HCC tumor tissues, in comparison with the adjacent non-tumor
tissues in clinical settings. More importantly, the repression of MAP2K3 was inversely correlated with the expression
of miR-21 in HCC. Further study demonstrated that the MAP2K3 was a novel direct target of miR-21, which was
experimentally validated by a miRNA luciferase reporter approach. In HepG2 cells, inhibition of miR-21 expression
with an adenoviral miR-21 sponge vector profoundly suppressed cell proliferation by up-regulating MAP2K3
expression at both mRNA and protein levels.
Conclusions: These results provide a clinical evidence that MAP2K3 may be a tumor repressor gene, and it is a
direct target of miR-21 in HCC, indicating an underlying mechanism by which miR-21 is able to directly target
MAP2K3 and inhibit its expression during the carcinogenesis of HCC, at both transcriptional and post-translational
levels. This study also suggests that targeting miR-21-MAP2K3 pathway may be a promising strategy in the
prevention and treatment of HCC.
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MicroRNAs (miRNAs) are evolutionarily conserved, en-
dogenous, single-stranded, non-coding RNA molecules
with a fundamental role in the regulation of gene ex-
pression [1]. miRNA binds a target gene through imper-
fect basepairing to the complementary sequences in the
3’untranslated region (3’UTR) of a gene to transcriptionally* Correspondence: 599040064@qq.com
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reproduction in any medium, provided the oror post-transcriptionally suppress its expression at the
mRNA or protein levels in many organisms, such as yeast,
fruit flies, worms, vertebrates, human and plants [2]. An
increasing number of studies has uncovered that the
expression of miRNAs is deregulated in many types of
cancers in comparison with matched non-neoplastic tis-
sues, including the hepatocellular carcinoma (HCC) [3].
Among them, miR-21 is aberrantly expressed in almost all
epithelial cell-derived solid tumors including breast, pan-
creas, lung, stomach, prostate, colon, head and neck, liver,
and esophageal cancers [4], as well as in hematological
malignancies such as leukemia, lymphoma and multipleThis is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.








1 56 Male 3.5 Tumor 295.26 -
Non-tumor 5324.96 +++
2 69 Male 7.4 Tumor 81.52 -
Non-tumor 868.44 +
3 27 Female 5.8 Tumor 697.8 -
Non-tumor 1509.85 +
4 42 Male 5.3 Tumor 237.82 -
Non-tumor 6341.06 +++
5 62 Female 4.4 Tumor 387.59 -
Non-tumor 7880.92 +++
6 33 Female 1.5 Tumor 145.52 -
Non-tumor 1554.87 +
7 52 Female 2.7 Tumor 4456.78 ++
Non-tumor 12345.41 +++
8 40 Male 6.2 Tumor 750.19 +
Non-tumor 4249.48 ++
9 47 Male 5.7 Tumor 208.14 -
Non-tumor 1824.86 +
10 72 Male 3.3 Tumor 234.06 -
Non-tumor 752.39 +
11 65 Male 4.0 Tumor 117.6 -
Non-tumor 6744.49 +++
12 51 Female 5.0 Tumor 519.31 -
Non-tumor 2628.37 +
13 60 Male 7.0 Tumor 1552 +
Non-tumor 566.92 +
14 30 Male 2.2 Tumor 1301.41 +
Non-tumor 15692.81 +++
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cated a variety of signaling pathways in which the
miR-21 plays a pivotal role in the carcinogenesis of
many types of cancers [7-11], and some of the signa-
ling molecules have been experimentally validated as
targets of miR-21, including phosphatase and tensin
homolog (PTEN) [10,12], programmed cell death 4
(PDCD4) [13], reversion-inducing -cysteine-rich pro-
tein with kazal motif (RECK) [14], and tropomyosin
alpha-1 chain (TPM1) [11].
Owing to the increase of hepatitis B virus (HBV) and
hepatitis C virus (HCV) infection, aflatoxin-contami-
nated food, and alcohol abuse, the incidence of hepato-
cellular carcinoma (HCC) is constantly rising in the last
two decades, particularly in China, where the HCC is
one of the most frequently occurring cancers [15]. Ge-
netic and expression profiling studies of HCC have de-
monstrated the alterations of a variety of mutations and
expression of oncogenes and/or tumor-suppressor genes
in the carcinogenesis of liver cancer, which are often
concomitant with the deregulation of an important sig-
naling pathway, such as p53, AP-1, and the mitogen-
activated protein kinases (MAPKs) pathway [16,17].
The MAPKs generally expressed in all cell types func-
tionally to transduce extracellular signals into various
intracellular responses [18]. In addition, dysregulation of
MAPK signaling pathway was often found in various
types of cancers, including the HCC, which was also
phenotypically validated in genetic mouse models with
impaired MAPK signaling [16,19]. Previous studies have
revealed that the expression of miR-21 was augmented
in malignant HCC tissues relative to the benign HCC
and normal liver tissues [20], however, its underlying
regulatory mechanism has not been fully elucidated yet.
Recently, Jia et al. found that mitogen-activated protein
kinase-kinase 3 (MAP2K3) was remarkably down-regu-
lated in breast cancer epithelial cells [21], we therefore
hypothesize that miR-21 may play a role in regulation
of MAP2K3 in HCC pathogenesis. In this study, we
found that the mitogen-activated protein kinase-kinase 3
(MAP2K3) was markedly down-regulated in human
HCC tissue, compared with adjacent non-tumor tissues
for the first time. The MAP2K3 was further identified
and experimentally validated as a novel target for
miR-21. This study might provide a new avenue for
comprehensively understanding the regulatory mech-




Human liver tissue was collected with a protocol ap-
proved by the Ethic Committee for the Conduct of Hu-
man Research at Ningxia Medical University. Writtenconsent was obtained from every individual according to
the Ethic Committee for the Conduct of Human Re-
search protocol. All participants were over 18 years of
age and provided written informed consent for the pub-
lication of the data. This study was approved by the
Ethic Committee for the Conduct of Human Research at
Ningxia Medical University.Human liver tumor samples
Fourteen liver tumor samples with histologic evidence of
HCC, and matched adjacent non-tumor tissues without
histological evidence of HCC were archival samples from
department of Medical Pathology Department, General
Hospital of Ningxia Medical University from 2007 to
2009 (Table 1) [22].
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Cell lines of human embryonic kidney 293 and human
hepatoma cell HepG2 were purchased from American
Type Culture Collection (Mannasas, VA, USA). The cells
were cultured and maintained at 37°C in a humidified
atmosphere of 5% CO2 95% air in dulbecco’s modified
eagle medium (DMEM) supplemented with 10% Fetal
Bovine Serum (FBS) and 1% pen/strep. Plasmid DNA
transfection was performed using TransLipid Transfec-
tion Reagent (Beijing TransGen Biotech Co. Ltd, Beijing,
China) per manufacturer’s instruction.Generation of recombinant adenoviral vectors
In order to generate adenoviral vectors overexpressing
miR-21, oligonucleotides of miR-21 forward (5’-TAG
GGGTACCCCTAAACCAACCAGCCAACC-3’) and re-
verse primer (5’- TATGCTCTA GAGCTCCGGCTT
TAACAGGTG -3’) were synthesized, and respective
restriction sites of Kpn I and Xba I were introduced
at 5’-ends, based on the sequence of human miR-21
(5’- uagcuuaucagacugauguuga-3’, MIMAT0000077) from
miRBase database. Similarly, in order to produce a miR-
21 sponge vector, annealed double strands containing 8×
tandem of binding sites that are perfectly complemen-
tary to miR-21 seeding sequence, was generated [23].
The sense sequence of miR-21 sponges with a Kpn I







stranded oligonucleotides were further modified with
appropriate restricted endonucleases and cloned into an
adenoviral shuttle vector, pAdTrack-CMV (Department
of Biological Chemistry, School of Medicine, Fudan
University, Shanghai, China). The resulted proviral shut-
tle plasmids were used for generation adenoviral vector
expressing miR-21 and miR-21 sponge following a pro-
tocol described previously [24,25]. The adenoviral vec-
tors were designated as Ad/pri-miR-21 for expressing
miR-21, and Ad/miR-21/inhibitor for expressing miR-21
sponge in this study. A control empty adenoviral vector,
Ad/con was also generated. The viral functional titra-
tion was essentially performed using Spearman-karber
method as described in the previous study [26].Infection of HepG2 cells with the adenovirus
The HepG2 cells were seeded in 6-well tissue plate and
grown to 80–90% confluence prior to infection. Cells
were infected with Ad/pri-miR-21, Ad/miR-21/inhibitor
or Ad/con at a multiplicity of infection (MOI) of 10, andthe cells were continued to culture for additional 24 h
before they were harvested for analysis.
Quantitative reverse transcription PCR (qRT-PCR)
Small RNAs of HepG2 cells were isolated using the
RNA purification kit following the manufacturer’s ins-
truction (RNAiso for Small RNA, TaKaRa, Dalian, China).
The quality of RNA was assayed by calculation of the
RNA integrity number (RIN) [27]. High quality of RNA
(RIN value was greater than 8.0) was used for reverse
transcription of the first-strand cDNA synthesis by reverse
transcription using M-MLV reverse transcriptase (TakaRa,
Dalian, China). The sequences of the primers used for re-
verse transcription of mature miRNA with stem-loop
structure were listed in Table 2, which were designed
according to the corresponding sequence from miRBase
database. The quantitative real-time RT-PCR (qRT-PCR)
was used for accessing miR-21 expression profile [28,29],
which was performed on a Roche lightcycler (LightCycler
480) using TaKaRa SYBR Green I kit (Takara, Dalian,
China); the thermal cycling condition for PCR was 95°C
for 30 sec, 40 cycles of 95°C for 5 sec, 60°C for 20 sec and
72°C for 20 sec, followed by 40°C for 20 min. The primer
sets used for RT-PCR of U6 promoter and miR-21 were
listed in Table 2. The control was always included to
normalize each reaction with respect to RNA integrity,
sample loading and inter-PCR variations. The relative ex-
pression ratio was calculated from the real-time PCR effi-
ciencies and the crossing point deviation of experimental
samples vs controls [30]. The specificity of PCR was deter-
mined by sequencing of the PCR products.
Experimental validation of miR-21 target
In order to validate the MAP2K3 mRNA was a target of
miR-21, a reporter plasmid containing luciferase with
the 3’UTR sequence of MAP2K3 mRNA was generated.
The following primers were designed based on GenBank
database (NM_ 002756.4), and were used for amplifica-
tion of wild-type and mutated 3’UTR of MAP2K3
mRNA: the sequence of common forward primer was
5’-GGACTAGTGCGGTTCCCTTACGAGTC-3’, reverse
primer for the wild-type of MAP2K3 mRNA 3’UTR was
5’-CGACGCGTCCAAAGCCGGGATAGAGG-3’, and the
reverse primer for mutated MAP2K3 mRNA 3’UTR was
5’-CGACGCGTGATCTCAGGTGTGGGTGAGCACTG
C-3’; restriction sites of Spe I and Mlu I were also
introduced in the forward and reverse primers, re-
spectively. The cDNA generated from HepG2 RNA was
used as templates for amplification of MAP2K3 3’UTR
fragment by a PCR assay. The wild-type and mutated
3’UTR fragment were then cloned into the downstream
of luciferase reporter gene of pMIR-Report vector
(Invitrogen, Grand Island, NY, USA), by which the re-
spective MAP2K3 mRNA luciferase reporter vectors,
Table 2 The sequences of primers used for reverse transcription and PCR
Application Primer Sequence (5’→3’)
Reverse transcription miR-21 RT CTCAACTGGTGTCGTGGAGTCGGCAATTCAGTTGAGTCAACATC
U6 RT AACGCTTCACGAATTTGCGT
qRT-PCR of miR-21 Common primer CTCAACTGGTGTCGTGGA
miR-21 PCR ACACTCCAGCTGGCTAGCTTATCAGACTGATG
qRT-PCR of U6 U6 promoter forward CTCGCTTCGGCAGCACA
U6 promoter reverse AACGCTTCACGAATTTGCGT
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and pMIR-Report/Mut-MAP2K3 (containing a mutated
3’UTR) were generated. The specificity of miR-21 tar-
geting MAP2K3 mRNA was ascertained by co-trans-
fection plasmid DNA of pAd/pri-miR-21, pAd/miR-21/
inhibitor or pAd/con and pMIR-Report/MAP2K3 or
pMIR-Report/Mut-MAP2K3 into 293 T cells and deter-
mined by the relative activity of firefly luciferase unit
(RLU) at 48 h post-transfection using a dual-luciferase Re-
porter assay kit (Promega, Madison, WI, USA). A Renilla
luciferase expressing plasmid pRL-TK (Promega, Madison,
WI, USA) was always included in the transfection to
normalize the efficiency of each transfection [31].
Western blotting analysis
Whole cell lystaes (75 μg) were prepared in a lysis buffer
(50 mM Tris-HCl, pH 7.5, 5 mM EDTA, 150 mM NaCl,
0.5% NP-40), and were resolved by a 10% sodium
dodecyl sulfate (SDS)-polyacrylamide gel (SDS-PAGE),
followed by being transferred to a PVDF membrane
(Millipore, USA). The membranes were probed with
rabbit anti-MAP2K3 antibody and anti-GAPDH anti-
body (Boster, Wuhan, China) or (1:200, Boster, Wuhan,
China) were for the interested protein MAP2K3 and
endogenous GAPDH for loading control, respectively.
The blots were developed using the enhanced chemi-
luminescence (ECL) reagent (Amersham Biosciences,
Piscataway, NJ, USA) after they were incubated with
the appropriate peroxidase labeled secondary anti-
bodies. The protein expression levels were quantified
by optical densitometry using ImageJ Software version
1.46 (http://imagej.nih.gov/ij/). Fold change was calcu-
lated as the ratio between the net intensity of each
sample divided by control GAPDH and the Ad/pri-
miR-21, Ad/miR-21/inhibitor and Ad/con infected sam-
ples divided by the GAPDH [32].
MTT assay
Cell proliferation was determined by using the MTT cell
proliferation kit (Solarbio, Beijing, China). 5×103 of
HepG2 cells were seeded in each 96-well plate and
allowed to adhere overnight. The cells were then in-
fected with adenovirus vector at MOI of 10 for the indi-
cated times prior to they were used for MTT assay perthe manufacturer’s instruction (Bio-Rad Laboratories,
Inc., Irvine, CA, USA).Immunohistochemistry staining
The expression of MAP2K3 in clinic human HCC and
matched adjacent non-tumor tissues was evaluated by
immunohistochemistry staining using rabbit anti-
MAP2K3 antibody (1:100, Boster, Wuhan, China). The
archival paraffin-embedded sections (5 μm) were de-
paraffinized and rehydrated through graded alcohol so-
lution. Tissue sections were microwaved in 10 mM
sodium citrate pH 6.0 for 13 minutes and cooled down
to room temperature (RT) for antigen retrieval. Followed
by treating the sections with 0.3% hydrogen peroxide in
phosphate buffered saline (PBS) for 15 minutes to inacti-
vate endogenous peroxidase before they were blocked
with blocking buffer (5% donkey serum in PBS) for 2 h
at RT. The rabbit anti- MAP2K3 antibody was then ap-
plied (1:100 in blocking buffer) on the section and incu-
bated overnight at 4°C. Paralleled sections incubated
with normal rabbit IgG was used for negative controls.
After washing for 3 × 5 min in PBS, sections were incu-
bated with peroxidase labeled donkey anti-rabbit IgG
(ZSGB-Bio ORIGENE, Beijing, China) (1:200 in blocking
buffer) for 30 minutes at RT. The MAP2K3 signal was
developed with 3, 3'-diaminobenzidine (DAB) peroxidase
substrate, followed by counterstaining with hematoxylin
if it was applicable. The stained sections were examined
and photographed on a Nikon Optiphot II microscope
equipped with a camera. The expression of MAP2K3
protein was arbitrarily scored from -, + to +++, based on
the intensity and number of positive cells, by a single ex-
perienced pathologist (Table 1). The non-counterstained
sections were also randomly imaged using a 10× ob-
jective lens for five fields of each section, and three sec-
tions for each sample were evaluated. The obtained
images were then for a semi-quantitative analysis of the
MAP2K3 expression by measuring the integrated ab-
sorbance (IA) using image analysis software Image-Pro
Plus 6.0 (IPP6.0, Media Cybernetics, Silver Spring, MD,
USA), and the average of the IA values of each sample
was used as an index of the expression of MAP2K3 ex-
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All data collected in this study was obtained from at
least three independent experiments for each condition.
SPSS15.0 analysis software was used for the statistic ana-
lysis. Statistical evaluation of the data was performed by
one-way ANOVA and t-test for comparison of diffe-
rences between the two groups. A value p<0.05 set to
represent a statistical difference. Data was presented as
the mean ± standard deviations (SD).+++
E
++
Figure 1 Immunohistochemistry (IHC) staining determined
MAP2K3 expression in human HCC tumor and matched
adjacent tissues. A-D: Representative images of MAP2K3 protein
expression determined by IHC staining. A: An image represented
a negative (-) expression of MAP2K3 expression; B: An image
represented a low level (+) expression of MAP2K3, which showed
a weak immunoreactive staining in cytoplasm; C: An image
represented a negative (++) expression of MAP2K3 expression; D: AnResults
MAP2K3 is downregulated in human hepatocellular
carcinoma
To explore clinical relevance of MAP2K3 with the pa-
thogenesis in human HCC, the expression of MAP2K3
was first evaluated in HCC tumor tissues and the ad-
jacent non-tumor tissues by immunohistochemistry
staining against anti-MAP2K3 antibody. Immunohisto-
chemistry staining showed predominantly cytoplasmic
localization of MAP2K3, with a subset of hematopoietic
cells exhibited perinuclear localization for this protein
(Figure 1A-1D). Surprisingly, the expression of MAP2K3
was strikingly suppressed in all malignant tumor cells
from the fourteen examined archival HCC samples,
relative to the adjacent non-tumor tissues, which was
supported by a semi-quantitative analysis using an
index of the integrated absorbance (IA) for the IHC
staining (Figure 1E, Table 1). This result implied that
MAP2K3 might be an important signaling molecule
that plays a tumor suppressor role in the carcinoge-
nesis of HCC.image represented a high level (+++) expression of MAP2K3, which
exhibited a strong IHC staining in cytoplasm and perinuclear
localization (arrowhead). E: Semi-quantitative analysis of MAP2K3
protein expression using integrated absorbance (IA) in human HCC
tissues. Value was expressed as the average values from each
individual sample of HCC tumor tissues or its matched adjacent
tissue. The total average value of IA in the HCC tumor tissues was
significantly greater as compared with the matched adjacent tissues
(p<0.05, n = 14). Data was expressed as mean ± SD for 14 sets
of samples.MAP2K3 mRNA is a target of miR-21
Since miR-21 has been demonstrated to be elevated in
many types of cancer, including the HCC. In order to ex-
perimentally validate whether MAP2K3 is a potential
target of miR-21 in HCC. Luciferase reporter vector
containing a 3’UTR of MAP2K3 mRNA (pMIR-Report/
MAP2K3 3’UTR), or a mutated 3’UTR (pMIR-Report/
Mut-MAP2K3 3’UTR) were first constructed (Figure 2A).
The HepG2 cells were co-transfected with pMIR-Report/
MAP2K3 3’UTR or pMIR-Report/Mut-MAP2K3 3’UTR,
and proviral plasmid pAd/con, pAd/pri-miR-21 or pAd/
miR-21/inhibitor. The results of relative luciferase activity
showed a 3.9-fold decrease and an 1.6-fold increase in the
cells transfected with pAd/pri-miR-21 and pAd/miR-21/
inhibitor, respectively, in comparison with the pAd/con
transfected cells (Figure 2B, 2C). There was no significant
change of luciferase activity in the cells transfected with
pAd/con or pMIR-Report/Mut-MAP2K3 3’UTR plasmid
DNA (Figure 2B, 2C). This data indicated that MAP2K3
might be a potential target for oncomir miR-21 in HepG2
cells.miR-21 represses MAP2K3 expression in HepG2 cells
We next sought to explore whether miR-21 was capable
of regulating MAP2K3 in hepatoma cell, HepG2 cells
were infected with Ad/pri-miR-21 and Ad/miR-21/in-
hibitor adenoviral vectors. Although miR-21 has been
reported highly expressed in HCC HepG2 cells [13], an
18-fold augmentation and 3-fold inhibition of miR-21
expression were still observed in cells infected with Ad/
pri-miR-21 and Ad/miR-21/inhibitor as determined by a
qRT-PCR assay [28,29], in comparison with the cells
infected with Ad/con, respectively (Figure 3). The total
cell lysates were harvested for immunoblotting analysis
A
human MAP2K3 3‘UTR 5’ …TGCTCACCCACACCATAAGCTA…3’
hsa-miR-21 3’… AGTTGTAGTCAGACTATTCGAT…5’
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Figure 2 Validation of MAP2K3 mRNA as a target of miR-21. (A): Sequence of potential binding site of miR-21 in the 3’UTR of MAP2K3
mRNA (top panel), mutations were introduced into the binding site for generation of mutated MAP2K3 3’TUR (bottom panel). (B and C):
Validation of miR-21 target using MAP2K3 3’UTR luciferase reporter. Cells co-transfected with pMIR-Report/MAP2K3 3’UTR (WT) or pMIR-Report/
Mut-MAP2K3 3’UTR (Mut) and pAd/pri-miR-21 (B), pAd/miR-21/inhibitor (C), and pAd/con plasmids showed a decreased luciferase activity in
pAd/pri-miR-21 cells (B). Luciferase activity after site directed mutagenesis of the 3’UTR of MAP2K3 mRNA in the miR-21 seed sequence
(pMIR-Report/Mut-MAP2K3) was significantly higher with respect to the pMIR-Report/MAP2K3 vector transfected cells (B and C). Results
represented the mean ± SD from three independent triplicated experiments (N=9).
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immunoblotting result demonstrated that the MAP2K3
protein expression was down-regulated by 0.6-fold in cells
infected with Ad/pri-miR-21, as compared with theAd/con (Figure 4); of note, the MAP2K3 expression was
augmented by 1.8-fold in cells infected with Ad/miR-21/
inhibitor virus (Figure 4). These results suggested that





























Figure 3 miR-21 expression in HepG2 cells. The expression of
miR-21 in HepG2 cells infected with Ad/pri-miR-21, Ad/miR-21/
inhibitor or Ad/con virus was determined by a qRT-PCR assay.
Significantly increased expression of miR-21 was detected in the
cells infected with adenovirus Ad/pri-miR-21 (p<0.05); in contrast, a
significantly decreased expression of miR-21 was observed in Ad/
miR-21/inhibitor infected cells (p<0.05). Compared with pAd/con
group, *: p<0.05. Results represented the mean ± SD from three
independent triplicated experiments (N=9).
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levels, indicative of an underlying mechanism of miR-21
in carcinogenesis of HCC.
Inhibition of miR-21 expression arrests the proliferation
of HepG2 cells
Abundant miR-21 expression was detected in HCC
HepG2 cells (Figure 3). In order to better characterize
the impact of miR-21 on cancer cell proliferation, the
endogenous expression of miR-21 expression was knock
down by transduction of miR-21 sponge into HepG2

















Figure 4 miR-21 targets MAP2K3 mRNA. The HepG2 cells were
infected with Ad/pri-miR-21, Ad/miR-21/inhibitor or Ad/con
adenoviral vector. The expression of MAP2K3 was detected by
immunoblotting analysis against anti-MAP2K3 antibody. Compared
with Ad/con group, *: p<0.05. Data in A represented the mean ± SD
from three independent triplicated experiments (N=9).of miR-21 sponge showed a significant inhibition of cell
proliferation in HepG2 cells, in comparison with those
transduced with Ad/con, as determined by an MTT
assay (Figure 5). This study was consistent with other
findings on the contribution of miR-21 as an oncomir
in HCC and a potential target for HCC treatment
[13,34-36].
Discussion
Hepatocellular carcinoma (HCC) is one of the most
common cancers, which ranks as the third most cancer-
related death worldwide [37]. Deregulated expressions of
several miRNAs were found correlate with the patho-
logic and clinical characteristics of HCC [3]. miR-21,
one of the most prominent miRNAs involved in the de-
velopment and progression of many types of cancers,
acts as an oncomir in the carcinogenesis of HCC
through a mechanism of targeting multiple targets in-
volved in various signaling pathways [34]. miRNA
microarray analysis has revealed that miR-21 was dra-
matically elevated in HCC tumor cells, with significant
reductions of the expressions of several tumor suppres-
sor genes, including PTEN, PDCD4, RECK and TPM1
(PTEN) [10-14]. Therefore, identification of novel target
of miR-21 will allow us to dissect the underlying signa-
ling pathways regulating liver carcinogenesis, which is
crucial for developing novel agents for target therapies of
HCC. In the present study, we identified that MAP2K3
was a novel direct target of miR-21. The study of loss-of-
function of miR-21 by transduction of miR-21 sponge in
HepG2 cells also indicated that miR-21 might regulate
cell proliferation, apoptosis and invasiveness partially
by targeting MAP2K3 [16,34].
miR-21 has been proposed to contribute to carcino-
genesis by targeting several key signaling regulating in-























Figure 5 Impact of miR-21 on HepG2 cell proliferation. HCC
HepG2 cells were infected with Ad/miR-21/inhibitor (miR-21
sponges) or pAd/con virus at MOI 0f 10, the index of cell
proliferation was assessed by an MTT assay from 24 to 72 hours.
Compared with Ad/con group, *: p<0.05. Data in A represented the
mean ± SD from three independent triplicated experiments (N=9).
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instance, miR-21 enhanced the cell proliferation by tar-
geting PDCD4 in cervical cancer HeLa cells [39] and
gastric cancer [9]. Other instances of miR-21 targeted
signaling pathways included TPM1 in breast cancer
MCF-7 cells [11], and Matrix Metalloproteinase regula-
tors in glioma cells [14]. The roles of miR-21 in carcino-
genesis were also demonstrated by approaches of
gain-and/or loss-off-function using transgenic mouse
models [40,41]. Using a transgenic mouse model able to
conditional overexpressing miR-21 in a tissue-specific
manner, in which the expression of miR-21 was under
the control of a tissue-specific Nestin promoter, and the
transgenic cassette could be conditional knockout by
doxycycline-induced Cre-LoxP system, Medina et al.
found that over-expression of miR-21 was able to led to
a pre-B malignant lymphoid-like phenotype in these
mice. In contrast, turning-off transgenic miR-21 expres-
sion in the animals led to a complete tumor regression
in few days [40]. Similarly, loss-of-function study using a
non-small cell lung cancer (NSCLC) transgenic mouse
model also suggested that genetic deletion of miR-21
allele was capable of partially protecting the mice from
tumor formation [41]. These supportive in vivo data
strongly suggest that miR-21 is a novel therapeutic target
for cancer prevention and treatment.
The emerging of miRNA “sponge” provides a valuable
tool for miRNA loss-of function studies in cell lines and
transgenic organisms, with several advantages including
the a broad range of specificity, applicability and flexibil-
ity over chemically modified antisense oligonucleotide
inhibitors [23]. A number of studies have demonstrated
the application of miRNA sponges with respect to cell
type, deliver vector, and type of miRNA targeted, to
dominantly negative inhibit the activity of targeted
miRNA in cell lines and transgenic organisms [23]. In
the this study, an adenoviral vector of miR-21 sponge
that containing a tandem of eight binding sites of miR-
21 was generated and tested in HCC HepG2 cells, the
HepG2 cells transduced with the sponges showed a
significant inhibition of miR-21 expression, and as a
consequence, the expression of new identified miR-21
targeted gene, MAP2K3 was augmented.
The MAPKs generally expressed in all cell types func-
tionally to transduce extracellular signals into various
intracellular responses, and at least four subfamilies
of MAPKs have been discovered: extracellular signal-
regulated kinase 1 and 2 (ERK1/2), Jun N-terminal ki-
nases (JNKs), P38 MAPKs and ERK5. These distinct
MAPK pathways share several common upstream ki-
nases and various downstream targets, suggesting they
may crosstalk with one another in various contexts
[18]. The mitogen-activated protein kinase-kinase 3
(MAP2K3) belongs to a dual specificity MAPK kinasegroup (MKK-) and is activated by MKK kinase (MKKK)
proteins (MEKK1–4) through Ser-189 and Thr-193 phos-
phorylation. MAP2K3 is an upstream activator of the p38
MAPK protein [42]. Recent studies found that MAP2K3
was down-regulated in immortal human breast epithelial
cells and that up-regulation of MAP2K3 expression pro-
moted cell senescence [21]. Zhu et al. found that miR-21
was up-regulated in HCC cells and tissues, which was as-
sociated with the capacity of cancer cell migration and
invasion in HCC, where the miR-21 expression was
inversely correlated with the protein expression of its
targeted gene, programmed cell death 4 (PDCD4) and sig-
naling molecules of its downstream pathway [13]. Consist-
ent with this finding, the result present in this study for
the first time demonstrated that MAP2K3 was a novel tar-
get for miR-21 in HCC, in which MAP2K3 expression
was inversely correlated with the miR-21, suggesting an
underlying mechanism by which the elevated miR-21
post-transcriptionally down-regulates MAP2K3 signaling
in HCC development.Conclusions
These results provide a clinical evidence that MAP2K3
may be a tumor repressor gene, and it is a direct target
of miR-21 in HCC, indicating an underlying mechanism
by which miR-21 is able to directly target MAP2K3 and
inhibit its expression during the carcinogenesis of HCC,
at both transcriptional and post-translational levels. We
also suggest that targeting miR-21-MAP2K3 pathway
may be a promising strategy in the prevention and treat-
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